Clinical Trial

Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with p53 mutation.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-10-12; most recent amendment 2024-01-02.
Status change: Not Yet Recruiting → Recruiting 2023-12-12
Trial Details
NCT Number NCT06088030
Lead Sponsor Yang Li
Collaborators: Ruijin Hospital
Conditions Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations
Enrollment 50 participants
Start Date 2023-12-13
Primary Completion 2031-12-14 (estimated)
Study Completion 2031-12-14 (estimated)
Updated on ClinicalTrials.gov 2024-01-03